FIELD: pharmaceuticals.
SUBSTANCE: present invention refers to compounds of formula (1a) or its pharmaceutically acceptable salt, where q equals 1; r is equal to 1 or 2; s equals 0 or 1, wherein sum of r and s equals 1 or 2; Q is CR1R2NR5R6, NR5R6, OR7, SR7; R1 is selected from hydrogen or C1-6 alkyl group; R2 is selected from hydrogen or C1-6 alkyl group; R3 denotes hydrogen; R4 represents hydrogen or C1-6 alkyl group; R5 is selected from OR7; C1-6 non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and in which one or two but not all carbon atoms of the hydrocarbon group can be optionally replaced with a heteroatom selected from O, N and S and their oxidised forms; and a group W or CH2W, where W is 5- or 6-member aromatic ring containing 0, 1, 2 or 3 heteroatoms selected from O and N; R6 is selected from COR7; COOR7; CH2COR7; CH2COOR7; C1-6 non-aromatic hydrocarbon group, which is optionally substituted with one to six fluorine atoms and in which one or two but not all carbon atoms of the hydrocarbon group can optionally be replaced with heteroatom O; or C3-6 cycloalkyl group; and R7 is selected from hydrogen, C1-6 alkyl group, which is optionally substituted with one to six fluorine atoms and in which one carbon atom can optionally be replaced with heteroatom N; and when Q is group OR7 or SR7, R7 is selected from a group W or (C1-4 alkyl)W, where W is phenyl; and the dashed line, which shows an optional second carbon-carbon bond, is absent. In addition, specific compounds, pharmaceutical compositions containing compounds of formula (1a) or specific compounds are disclosed.
(1a).
EFFECT: there are prepared and described new compounds which are muscarinic receptor and/or M4 agonists and are suitable for treating diseases mediated by muscarinic receptors M1/M4.
22 cl, 1 dwg, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
BICYCLIC NITROGEN-CONTAINING COMPOUNDS AS AGONISTS OF M1 MUSCARINIC RECEPTORS | 2019 |
|
RU2811601C1 |
PHARMACEUTICAL COMPOUNDS | 2018 |
|
RU2767857C2 |
BICYCLIC NITROGEN-CONTAINING COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | 2015 |
|
RU2685230C2 |
OXADIAZOLES AS MUSCARINIC RECEPTOR AGONISTS M AND/OR M | 2019 |
|
RU2817018C2 |
5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | 2020 |
|
RU2820477C1 |
CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | 2011 |
|
RU2565596C2 |
MENIN-MLL INTERACTION INHIBITORS | 2017 |
|
RU2799820C2 |
PROTEIN TYROSIN PHOSPHATASE INHIBITORS | 2020 |
|
RU2799449C2 |
NEW SULPHONAMIDE CARBOXAMIDE COMPOUNDS | 2018 |
|
RU2808572C2 |
SPIRO-FUSED PIPERIDINE DERIVATIVES FOR APPLICATION AS INHIBITORS OF EXTERNAL MEDULLAR LAYER POTASSIUM CHANNEL | 2013 |
|
RU2642066C2 |
Authors
Dates
2020-11-25—Published
2016-08-03—Filed